<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511771</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919A2433</org_study_id>
    <nct_id>NCT00511771</nct_id>
  </id_info>
  <brief_title>A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</brief_title>
  <official_title>A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To provide tegaserod to eligible women adult patients who did not have satisfactory&#xD;
      improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic&#xD;
      constipation (CIC) symptoms with other available treatment(s) and / or patients who had&#xD;
      satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Irritable Bowel Syndrome With Constipation</condition>
  <condition>Chronic Idiopathic Constipation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod</intervention_name>
    <description>Tegaserod maleate</description>
    <other_name>Zelnorm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. For patients with IBS-C: Women of 18-54 years of age with IBS-C according to the Rome&#xD;
             III criteria.&#xD;
&#xD;
          2. For patients with Chronic Idiopathic Constipation: Women of 18-54 years of age with&#xD;
             CIC according to the Rome III criteria .&#xD;
&#xD;
          3. Patients who did not have satisfactory symptom improvement of their IBS-C or CIC&#xD;
             symptoms with other available treatment(s) and / or patients who had satisfactory&#xD;
             improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.&#xD;
             Satisfactory symptom improvement will be assessed by the patient.&#xD;
&#xD;
          4. Patients signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of or current diagnosis of cardiovascular ischemic disease (e.g., angina&#xD;
             pectoris, myocardial infarction, transient ischemic attack or stroke and including&#xD;
             findings suggestive of ischemia on an ECG such as changes in ST segment and T waves,&#xD;
             and / or Q wave)&#xD;
&#xD;
          2. Patients who have uninvestigated symptoms suggestive of a cardiovascular ischaemic&#xD;
             disease such as chest pain or chest discomfort, shortness of breath, sudden onset of&#xD;
             weakness of the arms or the legs, difficult talking or loss of sensation etc&#xD;
&#xD;
          3. Presence of any cardiovascular risk factors according to the NIH guideline [NIH&#xD;
             Publication No. 01-3670] (such as hypertension, hyperlipidemia, diabetes mellitus,&#xD;
             active smoking, obesity and family history of premature coronary heart disease) as&#xD;
             assessed by the investigator&#xD;
&#xD;
          4. Clinical evidence of significant (as judged by the Investigator) respiratory,&#xD;
             cardiovascular, renal, hepatic-biliary, endocrine, psychiatric or neurologic diseases&#xD;
             or presence of abdominal adhesions&#xD;
&#xD;
          5. History of or current eating disorder such as anorexia or bulimia or compulsory&#xD;
             overeating.&#xD;
&#xD;
          6. Uncompensated depression or anxiety or suicidal ideation or behavior.&#xD;
&#xD;
          7. Diagnosis of mega-rectum or colon, a history of intestinal obstruction, congenital&#xD;
             anorectal malformation, clinically significant rectocele, or any evidence of&#xD;
             intestinal structural abnormality including gastrointestinal resection that affected&#xD;
             bowel transit or any evidence of intestinal carcinoma, of inflammatory bowel disease&#xD;
             or of alarm symptoms such as weight loss, rectal bleeding, or anemia&#xD;
&#xD;
          8. Evidence of cathartic colon or a history of drug (including laxative) or alcohol&#xD;
             abuse, that in the Investigator's opinion, the patient is likely to continue to abuse&#xD;
             these substances during the tIND program period&#xD;
&#xD;
          9. Pregnant women or breastfeeding women; fertile women who are not currently practicing&#xD;
             medically approved method of contraception&#xD;
&#xD;
         10. Participating in other investigational studies concurrently or within 1 month prior to&#xD;
             entering this tIND program&#xD;
&#xD;
         11. Hypersensitive to tegaserod or to any of the excipients&#xD;
&#xD;
         12. Patients who had tolerability or safety concerns with prior use of tegaserod.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
  </eligibility>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>November 16, 2010</last_update_submitted>
  <last_update_submitted_qc>November 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Tegaserod, treatment IND, irritable bowel syndrome with constipation, IBS-C, chronic idiopathic constipation, CIC, chronic constipation, CC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

